1. Home
  2. RGS vs TCRX Comparison

RGS vs TCRX Comparison

Compare RGS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

HOLD

Current Price

$23.00

Market Cap

66.3M

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
TCRX
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.3M
57.9M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
RGS
TCRX
Price
$23.00
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.50
AVG Volume (30 Days)
13.3K
490.8K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
20.24
16.18
EPS
0.64
N/A
Revenue
$210,134,000.00
$2,816,000.00
Revenue This Year
N/A
$286.83
Revenue Next Year
N/A
N/A
P/E Ratio
$35.34
N/A
Revenue Growth
3.52
N/A
52 Week Low
$15.00
$0.88
52 Week High
$31.50
$2.57

Technical Indicators

Market Signals
Indicator
RGS
TCRX
Relative Strength Index (RSI) 43.75 51.47
Support Level $21.67 $0.91
Resistance Level $23.27 $1.08
Average True Range (ATR) 0.84 0.07
MACD 0.16 0.01
Stochastic Oscillator 51.44 83.78

Price Performance

Historical Comparison
RGS
TCRX

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: